Omega-3 (n-3) and 6 (n-6) polyunsaturated fatty acids (PUFAs) have been associated with reduced cognitive decline in observational studies. Hence, we examined the cross-sectional associations between cortical b-amyloid (Ab) and erythrocyte membrane PUFAs in 61 non-demented elderly individuals reporting subjective memory complaints from the Multidomain Alzheimer Preventive Trial placebo arm. Cortical-to-cerebellar standard uptake value ratios were obtained using [
Fatty acids, particularly in the phospholipid form, control the structure and function of cell membranes (Kaplan and Greenwood 1998; Yehuda et al. 1999; Bazinet and Lay e 2014) . The brain is highly enriched in lipids and contains very high amounts of long-chain polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (ARA, ) and docosahexaenoic acid (DHA, . These PUFAs, which are the major constituents of neural cell membrane phospholipids, belong to the omega 6 (n-6) and omega 3 (n-3) PUFA families, respectively. ARA and DHA are predominantly obtained from dietary sources, although synthesis from their essential fatty acid precursors, linoleic acid (LNA) and a-linolenic acid (ALA), occurs to a limited extent in the brain (Bazinet and Lay e 2014) . Hence, the brain is reliant on the uptake of ARA and DHA from the blood. Other less abundant n-3 PUFAs that are emerging to share overlapping as well as distinct roles to that of DHA include eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA: n-3) (Dyall 2015) . In the brain, PUFAs regulate neurotransmission, cell survival, and neuro-inflammation and thereby impact mood and cognition; thus, PUFAs have been implicated in the aetiology of a number of neurological disorders including schizophrenia and Alzheimer's disease (AD) (Bazinet and Lay e 2014) .
AD is characterised by the presence of cerebral b-amyloid (Ab), neurofibrillary tangles composed of hyper-phosphorylated tau and neurodegeneration (Hardy and Allsop 1991) . The presence of the apolipoprotein E e4 (ApoE4 e4) allele is the main genetic risk factor associated with sporadic disease; the predominant form of AD (Corder et al. 1993) . Longchain PUFAs have been shown to reduce Ab levels through altered processing of amyloid precursor protein (APP) in cell culture and animal models of disease (Lim et al. 2005; Perez et al. 2010; Grimm et al. 2011; Yang et al. 2011) . In accordance with the amyloid cascade hypothesis of AD, Ab is thought to be the main driver of AD pathology culminating in neurofibrillary tangle formation, which in turn precipitates neuronal loss and cognitive impairments (Hardy and Allsop 1991; Hardy and Higgins 1992) . Although PUFAs are associated with both reduced Ab levels in vitro and in animals (Perez et al. 2010; Yang et al. 2011) and with reduced cognitive decline in the elderly in observational studies (Heude et al. 2003; Milte et al. 2011) , the associations between PUFAs and Ab load in human brain has been poorly documented. To the best of our knowledge only one study to date has shown that serum DHA levels are reduced in elderly subjects positive for cerebral Ab (Yassine et al. 2016) . In addition, some, but not all (Sinn et al. 2012) randomised controlled trials (RCTs) have observed the therapeutic usefulness of n-3 PUFA supplementation, particularly DHA and EPA, in the prevention of cognitive decline in mild cases of AD (Freund-Levi et al. 2006; Chiu et al. 2008; Sinn et al. 2012) . Hence, we sought here to examine the associations between cortical Ab load and PUFAs in older adults at risk of developing dementia. We hypothesised that PUFAs, particularly n-3 PUFA would be negatively associated with cortical Ab load.
Methods
The (Vellas et al. 2014; Andrieu et al. 2017) (registration: NCT00672685) . MAPT was designed to assess the efficacy of n-3 PUFA supplementation (DHA + EPA) alone or in combination with a multidomain intervention (involving nutritional and exercise counselling and cognitive training) in slowing cognitive decline in older adults at risk of dementia (n = 1680). The rationale being that n-3 PUFA administration, physical exercise and cognitive activity may improve cognitive health (Coley et al. 2008; Vellas et al. 2014) . Subjects were randomised to one of the four MAPT groups (1 : 1 : 1 : 1 ratio), using computer-generated randomisation procedures stratified by centre. Allocation concealment was guaranteed. Subjects allocated to the n-3 PUFA supplementation arm were asked to consume two soft capsules daily as a single dose, containing 400 mg per capsule of DHA and a maximum amount of 112.5 mg per capsule of EPA for 3 years. This amounted to 800 mg of DHA per day and a maximum amount of 225 mg of EPA per day. The placebo group consumed two identical soft capsules per day for 3 years comprising flavoured paraffin oil.
Participants
A total of 271 subjects volunteered to participate in the MAPTflorbetapir ancillary study. At inclusion, participants were community-dwelling, men and women without dementia, aged ≥ 70, and who met at least one of the following criteria: subjective memory complaints, limitation in executing ≥ 1 Instrumental Activity of Daily Living, or slow gait speed (< 0.8 m/s). To rule out effects of the interventions on fatty acids levels and cortical Ab levels, analyses were carried out in individuals from the placebo group only (n = 70). Two participants were excluded because they developed dementia since baseline (clinical dementia rating ≥ 1) and seven participants were lacking data on erythrocyte membrane fatty acid levels at the clinical assessment closest to the PET scan. Thus, a total of 61 subjects were included in the analyses described here (Fig. 1) .
[ 18 F] Florbetapir PET PET scans were performed, using [ 18 F] florbetapir as previously described (Vellas et al. 2014; Del Campo et al. 2016) . In brief, all PET data acquisitions were begun 50 min after injection of a mean of 4 MBq/kg weight of [ 18 F]-Florbetapir. Radiochemical purity of [ 18 F]-Florbetapir was always superior to 99.5%. Regional standard uptake value ratios (SUVRs) were generated from semi-automated quantitative analysis with the whole cerebellum as the reference region. Cortical-to-cerebellar SUVRs (cortical-SUVRs) were obtained using the mean signal of the following predefined cortical regions: frontal, temporal, parietal, precuneus, anterior cingulate, and posterior cingulate as previously described (Joshi et al. 2012) .
A quality control based on semi-quantification process was also performed.
Fatty acid assessment
Fatty acids were measured in erythrocyte membranes. Erythrocyte membrane fatty acid concentration represents a reliable measurement of dietary habits, considering that fatty acids are stable in erythrocyte membranes for up to 3 months corresponding to the lifespan of a red blood cell (Arab 2003) . Furthermore, erythrocyte membrane fatty acid concentrations have been shown to reflect tissue concentrations (Harris et al. 2004) . In contrast, plasma levels of fatty acids (free, cholesteryl esters or phospholipid bound) reflect recent dietary intake over a time frame of a few days and therefore do not represent a true picture of steady-state fatty acid levels (Arab 2003) . Whole blood (5 mL) collected into EDTA blood collection tubes was centrifuged at 2000 g for 10 min at 4°C. The red blood cell pellet was separated from plasma and stored immediately at 4°C before measurement of fatty acids. Lipids were extracted from erythrocytes with a mixture of hexane and isopropanol (3 : 2 v/v) after acidification, which is required for the formation of fatty acid methyl esters (FAME) and serves to lyse the cells (Legrand et al. 2010) . Margaric acid (Sigma, St Louis, MO, USA) was added as an internal standard. Total lipid extracts were saponified and methylated. FAME were extracted with pentane and analysed by gas chromatography (GC) using an Agilent Technologies 6890N gas chromatograph with a split injector, a bonded silica capillary column (BPX 70, 60 m 9 0.25 mm; 0.25 lm film thickness) and a flame ionisation detector. Helium was used as a carrier gas, the column temperature program started at 150°C, increased by 1.3°C/min to 220°C and was held at 220°C for 10 min. Identification of FAME was based on retention times obtained for FAME prepared from fatty acid standards. The peak area under the curve was determined using ChemStation software (Agilent, Paris, France).
Independent variables
Although multiple fatty acids were measured by GC we made an a priori decision to examine only the following PUFA parameters in association with cortical Ab load since these parameters have been implicated in cognition in the elderly (Heude et al. 2003; Milte et al. 2011) : total n-3 and total n-6 PUFAs, ARA, LNA, DHA, EPA, DPA (n-3), ALA, sum DHA + EPA and the n-3:n-6 PUFA ratio (all expressed as % total fatty acids). We used blood sampling (either at baseline or 1-year) performed closest to PET scans.
Timing of assessments
The median and interquartile range (IQR) for the time interval between PET scan and closest clinical assessment was 69 (IQR: 48-96). The median and IQR for the time interval between PET scan and blood collection was 195 (IQR: 66-397).
Confounding variables
On the basis of data availability and the literature on dementia, we selected the following confounders: age at baseline, gender, education, cognitive status assessed at the clinical visit closest to PET scan (Mini mental state examination scores ranging from 0 to 30), time interval between PET scan and clinical assessment (in days), time interval between PET scan and blood collection (in days) and ApoE e4 status (carriers of at least one e4 allele vs. noncarriers).
Statistical analysis
Descriptive statistics are presented as mean AE standard deviation or absolute values/percentages as appropriate. After completing analysis of the primary hypotheses in MAPT (Andrieu et al. 2017) , we subsequently performed post hoc analyses, using multiple linear regression to evaluate the cross-sectional relationship between each erythrocyte membrane fatty acid variables and cortical-SUVR adjusting for all confounders in a two-step model. Model 1 included all confounders except ApoE4 e4 and model 2 included all confounders plus ApoE4 e4. This approach was deemed appropriate because the ApoE4 genotype was missing for 11.5% (n = 7/61) of the population. In order to facilitate comparability across regression models, we undertook sensitivity analysis on both the unadjusted model and model 1 restricted to participants with no missing information on confounders (n = 53). Adjustments for multiple testing were made using Bonferroni's principle and associations were considered significant at p ≤ 0.005 (adjustment for 10 comparisons). All analyses were performed using Stata version 14 (Stata Corp., College Station, TX, USA).
Results

Sample characteristics
Demographic and clinical characteristics of the participants included in this study are shown in Table 1 . The mean age of the 61 participants was approximately 75 years and around 60% of the population were female. Participants exhibited a high level of education and almost half of the participants No fatty acid data (n = 7) Fig. 1 Flowchart describing the participants/exclusions in the current study had a clinical dementia rating score of 0.5 and one-third of the subjects carried at least one ApoE e4 allele.
Erythrocyte membrane fatty acids
The concentrations of PUFAs in erythrocyte membranes are shown in Table 2 . The predominant forms of n-6 and n-3 PUFAs were LNA and DHA, respectively.
Erythrocyte membrane fatty acids and cortical Ab load Table 3 shows the cross-sectional associations of erythrocyte membrane fatty acid variables with cortical Ab load. No significant associations were found between cortical Ab load and erythrocyte membrane ARA, LNA, total n-6 PUFAs, DHA, EPA, DPA (n-3), ALA, DHA + EPA, total n-3 PUFAs, or the n-3:n-6 PUFA ratio after correction for multiple testing. Albeit weak, the association of cortical Ab with erythrocyte membrane ARA in model 1 after adjustment for age, sex, education, cognition, PET scan to clinical assessment interval and PET scan to blood collection interval was the closest to significance (p = 0.02). This trend remained evident when ApoE genotype was added to the regression model (model 2) (p = 0.04). Erythrocyte membrane LNA was also associated, but inversely, with cortical Ab load in regression model 1 (p = 0.02). However, this trend became less evident when ApoE genotype was added to the regression model (model 2) (p = 0.09).
Sensitivity analysis restricted to participants with no missing information shows similar results as the main analysis (Table S1) .
Next we performed two additional exploratory analyses. Firstly, we entered erythrocyte membrane DHA levels into the regression model (model 2) to determine whether the association between ARA with cortical Ab levels was independent of membrane DHA levels, considering that DHA can act as an ARA antagonist at high membrane concentrations (Luxwolda et al. 2011 ). The addition of DHA into the regression model only slightly affected the association of erythrocyte membrane ARA with cortical Ab load (B-coefficient 0.03, CI: 0.00, 0.06, p = 0.05). To explore the role of ApoE4 status on the associations of ARA and LNA with cortical Ab, we ran two separate multiple linear regression analyses stratified according to ApoE4 status (e4 carriers vs. non-carriers) and adjusted for age and sex. This exploratory analysis revealed that ARA was associated with cortical Ab load in ApoE e4 non-carriers (B-coefficient 0.03, CI: 0.00, 0.06, p = 0.03, n = 36), but not in ApoE e4 carriers (B-coefficient 0.02, CI: À0.04, 0.08, p = 0.57, n = 18). In contrast, LNA was not associated with cortical Ab load when subjects were stratified into ApoE e4 non-carriers (Bcoefficient 0.04, CI: À0.14, 0.22, p = 0.66, n = 36) and ApoE e4 carriers (B-coefficient 0.08, CI: À0.20, 0.35, p = 0.55, n = 18).
Discussion
In this study, we did not find any significant associations between cortical Ab load and erythrocyte membrane PUFAs in non-demented older adults reporting subjective memory complaints after correction for multiple testing. To the best of our knowledge, this is the first study relating erythrocyte membrane PUFAs with central Ab load.
The associations closest to significance were those between cortical Ab and ARA and Ab and LNA. A recent study has shown that ARA and its metabolites increase Ab production in cell culture and animal models of AD (Amtul et al. 2012). Metabolism of ARA gives rise to the omega 6-derived analogues of the eicosanoid family exhibiting high inflammatory potential (Calder 2002 ) and neuro-inflammation seems to be a central feature of AD (McGeer and McGeer 1999) . Therefore, it might be that increased inflammation is responsible for driving the increase in cortical Ab load and the positive association between ARA and Ab we demonstrate here supports this supposition. Interestingly, erythrocyte membrane LNA was inversely associated with cortical Ab load as demonstrated using multiple linear regression analysis adjusted for age at baseline, gender, education, cognitive status, time interval between PET scan and clinical assessment and time interval between PET scan and blood collection. However, this trend became less apparent when ApoE genotype was added to the regression model. Thus, reduced dietary LNA might be linked with increased Ab plaque deposition. Alternatively, fatty acid balance might be influenced by genotype (Ameur et al. 2012) or enzymatic changes with age (Block et al. 2008) . Indeed, specific fatty acid desaturase haplotypes, which encode the enzymes that perform the rate limiting step in the biosynthesis of n-3 and n-6 PUFAs from ALA and LNA respectively, have been associated with differential efficiencies in precursor conversion and hence fatty acid levels (Ameur et al. 2012 ). Furthermore, it is possible that reduced LNA might represent increased production of omega 6-derived eicosanoids in line with our inflammatory hypothesis.
Exploratory analysis of our data suggests that the association between cortical Ab and ARA might be specific to ApoE4 e4 non-carriers. Fatty acid metabolism could conceivably be modified by ApoE genotype and thus e4 carriers versus non e4 carriers might exhibit differential brain fatty acid bioavailability (Chouinard-Watkins and Plourde 2014), which in turn might impact upon brain Ab load and subsequent cognitive impairments. Indeed, it has been shown that plasma DHA levels show little change in ApoE e4 carriers despite supplementation (Plourde et al. 2009 ). Furthermore, some studies have shown that the protective cognitive effects of n-3 PUFAs are seen only in ApoE e4 non-carriers (Huang et al. 2005; Barberger-Gateau et al. 2007) . Consequently, the association of ARA with cortical Ab load warrants further research attention in relation to ApoE genotype.
We did not find any significant associations between cortical Ab and n-3 PUFAs. This is in contrast to our original hypothesis based on cell culture and animal models of AD, which have shown that PUFAs, particularly n-3 PUFAS, reduce Ab levels through altered processing of APP (Lim et al. 2005; Perez et al. 2010; Grimm et al. 2011; Yang et al. 2011) . In human subjects, it has been reported that serum DHA levels are reduced in elderly individuals with significant cerebral Ab load (Yassine et al. 2016) . Furthermore, dietary n-3 PUFA intake has been associated with lower plasma Ab levels in cognitively healthy elderly subjects (Gu et al. 2012) . Thus, the associations of n-3 PUFAs with central Ab deserves further investigation.
The strengths of the current study are the focus on elderly subjects who were free of clinical dementia, but at risk of its development and the simultaneous availability of both PET [ 18 F] florbetapir imaging data and a reliable and stable biological measure of PUFA levels. Nonetheless, there are ]florbetapir PET imaging. Model 1 and 2 contained fewer subjects due to missing data on confounders. Model 1 included 60 subjects and was adjusted for age, sex, education, cognition, time interval between PET scan and clinical assessment and time interval between PET scan and blood collection. Model 2 included 53 subjects and was adjusted for the same confounders as those described in model 1+ ApoE e4.
several limitations. We did not use a food frequency questionnaire to assess fish intake. Fatty acids, specifically ARA has been shown to exhibit differential tissue distributions (Chilton et al. 1996) and erythrocytes have been suggested to contain lower levels of PUFAs (Bates et al. 1997 ). Thus, it should be born in mind that erythrocytes might favour uptake of particular fatty acid types. The study had a small sample size and the cross-sectional nature (due to lack of longitudinal imaging data) precluded the examination of the relationship between erythrocyte membrane PUFA levels and the development of Ab plaques over time. It should also be noted that our study was not of a true crosssectional design since the PET scans were performed throughout the 3-year period of MAPT and the blood collection and clinical assessments for dementia rating were not performed on the same day as each other and the PET scans. However, the inclusion of PET scan to clinical assessment time interval and PET scan to blood collection time interval as confounders in regression models probably reduced this bias.
In conclusion, we have shown here that cortical Ab was not significantly associated with erythrocyte membrane PUFAs in older adults at risk of dementia. However, we provide some evidence that cortical Ab might be associated with erythrocyte membrane ARA and LNA. The Ab-ARA association appeared to be specific to ApoE4 e4 non-carriers. A longitudinal study examining the temporal association between Ab and PUFAs, with particular focus on ARA and LNA, would confirm or refute our findings as to whether PUFAs might modulate cognition via Ab-dependent mechanisms.
Ethical standards
Both the MAPT and PET sub-study were approved by the ethical committee in Toulouse (CPP SOOM II) and have therefore been performed in accordance with the 1964 Declaration of Helsinki and its later amendments. Written consent was obtained from all participants.
Acknowledgments and conflict of interest disclosure 'The MAPT study was supported by grants from the G erontopôle of Toulouse, the French Ministry of Health (PHRC 2008 (PHRC , 2009 ), Pierre Fabre Research Institute (manufacturer of the omega-3 supplement), Exhonit Therapeutics SA, Avid Radiopharmaceuticals Inc and in part by a grant from the French National Agency for Research called "Investissements d'Avenir" no. ANR-11-LABX-0018-01. The promotion of this study was supported by the University Hospital Center of Toulouse. The data sharing activity was supported by the Association Monegasque pour la Recherche sur la maladie d'Alzheimer (AMPA) and the UMR 1027 Unit INSERM-University of Toulouse III'. All authors declare no conflicts of interest. Sponsor's role: None.
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Table S1 . Sensitivity analysis examining the cross-sectional associations between erythrocyte membrane polyunsaturated fatty acid parameters and cortical b-amyloid load restricted to participants with no missing information.
